Current Report Filing (8-k)
February 26 2020 - 7:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM 8-K
CURRENT
REPORT Pursuant
to
Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of report (Date
of earliest event reported): February 26, 2020
Iradimed
Corporation
(Exact Name of Registrant as Specified
in Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
001-36534
|
73-1408526
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
1025 Willa Springs Dr., Winter Springs, FL
|
32708
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
(407) 677-8022
(Registrant’s Telephone Number,
Including Area Code)
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class:
|
|
Trading Symbol
|
|
Name of each exchange on which registered:
|
Common stock, par value $0.0001
|
|
IRMD
|
|
NASDAQ Capital Market
|
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On February 26, 2020, iRadimed
Corporation (the “Company”) issued a press release announcing the retirement of Francis Casey, Vice President
of Regulatory and Quality Assurance, effective June 30, 2020 after originating and leading the Company’s regulatory efforts
since 2004. iRadimed appointed Steven Kachelmeyer as Vice President of Regulatory
Affairs and Quality Assurance, succeeding Mr. Casey, effective March 10, 2020. Mr. Kachelmeyer will report to Leslie McDonnell,
President and Chief Executive Officer.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
IRADIMED CORPORATION
|
|
|
|
|
Date: February 26, 2020
|
|
|
By:
|
/s/Chris Scott
|
|
Name: Chris
Scott
|
|
Title: Chief
Financial Officer
|
iRadimed (NASDAQ:IRMD)
Historical Stock Chart
From Jul 2024 to Aug 2024
iRadimed (NASDAQ:IRMD)
Historical Stock Chart
From Aug 2023 to Aug 2024